Login to Your Account



BMS to Sell ImClone Stake for $1B

It's Official: Lilly Offers $70 per Share for ImClone in $6.5B Deal

By Jennifer Boggs


Tuesday, October 7, 2008
Indianapolis-based Eli Lilly and Co. officially emerged Monday as the $70-per-share bidder for ImClone Systems Inc., affirming last week's speculation on the Street, as it aims to pick up a pipeline that includes marketed EGFR inhibitor Erbitux and three late-stage oncology programs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription